NASDAQ:MLTX | Cash Flow Statement | MoonLake Immunotherapeutics

Complete source-backed cash-flow history.

Available history
2021-03-31 to 2026-06-30
Data captured

Historical Cash Flow Statement

DateNet incomeDepreciation and amortizationOperating cash flowCapital expenditureInvesting cash flowShare repurchasesDividends paidFinancing cash flow
2026-06-30-$61.81M
2026-03-31-$69.71M$845,000.00-$66.29M$0.00$98,000.00$30.64M
2025-12-31-$62.43M$751,000.00-$58.79M$0.00-$29.91M$72.4M
2025-09-30-$69.73M
2025-06-30-$55.22M
2025-03-31-$39.94M$378,000.00-$38.14M$35,000.00$56.25M$73.12M
2024-12-31-$45.61M$364,000.00-$48.47M$176,000.00-$147.33M$0.00$151,000.00
2024-09-30-$35.39M
2024-06-30-$24.27M
2024-03-31-$13.67M$328,000.00-$14.95M$212,000.00-$28.8M$50.00$50.98M
2023-12-31-$7.44M-$12.34M$284,000.00$116.87M$0.00$28.42M
2023-09-30-$9.43M
2023-06-30-$10.14M
2023-03-31-$9M-$9.02M$0.00$19.65M$0.00$0.00
2022-12-31-$17.11M-$11.6M$1.00$9.9M$3,791.00
2022-09-30-$10.11M
2022-06-30-$12.12M
2022-03-31-$15.88M-$14.19M$16,010.00-$16,010.00$15M
2021-12-31$34.78M$27.11M-$28.32M
2021-09-30-$6.29M
2021-06-30-$32.69M
2021-03-31-$76,291.00-$107,795.00-$58,063.00

Annual Cash Flow Statement

DateNet incomeDepreciation and amortizationOperating cash flowCapital expenditureInvesting cash flowShare repurchasesDividends paidFinancing cash flow
2025-12-31-$227.32M$2.62M-$196.01M$35,000.00$202.99M$146M
2024-12-31-$118.94M$1.39M-$116.59M$520,000.00-$205.6M$50.00$51.31M
2023-12-31-$36.01M$370,000.00-$42.78M$284,000.00-$25.18M$0.00$479.7M
2022-12-31-$49.97M$164,783.00-$55.89M$16,009.00-$32.34M$0.00$119.69M
2021-12-31-$4.54M-$611,071.00-$58,063.00